What is HC Wainwright's Estimate for HRTX Q2 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for Heron Therapeutics in a report issued on Monday, June 9th. HC Wainwright analyst B. Folkes expects that the biotechnology company will post earnings of $0.00 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics' Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.21 EPS, FY2028 earnings at $0.43 EPS and FY2029 earnings at $0.44 EPS.

Several other equities analysts have also commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, April 11th. Wall Street Zen raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, June 6th.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX traded down $0.08 during midday trading on Wednesday, reaching $1.93. The stock had a trading volume of 748,067 shares, compared to its average volume of 2,236,826. The stock has a 50-day moving average of $2.02 and a 200-day moving average of $1.90. The company has a market capitalization of $294.45 million, a price-to-earnings ratio of -10.72 and a beta of 1.16. Heron Therapeutics has a 12-month low of $1.04 and a 12-month high of $3.73.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million.

Institutional Trading of Heron Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Principal Financial Group Inc. increased its holdings in shares of Heron Therapeutics by 10.6% in the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock valued at $174,000 after acquiring an additional 10,909 shares during the last quarter. New York State Common Retirement Fund increased its position in Heron Therapeutics by 3.2% in the 4th quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company's stock worth $2,021,000 after purchasing an additional 41,062 shares during the last quarter. Cutter & CO Brokerage Inc. increased its holdings in shares of Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 13,600 shares during the last quarter. Anfield Capital Management LLC boosted its stake in Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock valued at $182,000 after purchasing an additional 6,264 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock worth $1,692,000 after acquiring an additional 9,418 shares during the period. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.